Neurotrope has announced the launch of a Phase 2 clinical trial to investigate the long-term use of bryostatin-1 for moderate and moderately severe Alzheimer’s disease. The company expects to dose the first patient later this year. “We are very excited to advance Bryostatin-1 to its next phase of development,” Daniel Alkon, MD, president and chief scientific officer of Neurotrope said in a press release. Bryostatin-1 is a small molecule designed to penetrate the blood-brain barrier…
You must be logged in to read/download the full post.
The post Neurotrope Launches Long-term Trial of Bryostatin-1 appeared first on BioNewsFeeds.